{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:37:24Z","timestamp":1761863844524,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":1032,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Glycotope GmbH, Berlin, Germany"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1136\/esmoopen-2017-000303","type":"journal-article","created":{"date-parts":[[2018,2,13]],"date-time":"2018-02-13T10:00:14Z","timestamp":1518516014000},"page":"e000303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas"],"prefix":"10.1016","volume":"3","author":[{"given":"Walter","family":"Fiedler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Cresta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Schulze-Bergkamen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"De Dosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Weidmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tessari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antje","family":"Danielczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Goletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Zurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Salzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/esmoopen-2017-000303_bb0010","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000303_bb0015","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000303_bb0020","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2010.33.5091","article-title":"Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status","volume":"29","author":"Van Cutsem","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000303_bb0025","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000303_bb0030","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2008.18.0463","article-title":"Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan","volume":"27","author":"Bibeau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000303_bb0035","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ejca.2012.01.007","article-title":"Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer","volume":"48","author":"Rodr\u00edguez","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2017-000303_bb0040","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1158\/1078-0432.CCR-12-0989","article-title":"GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab","volume":"19","author":"Gerdes","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000303_bb0045","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1136\/esmoopen-2017-000303_bb0050","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1136\/esmoopen-2017-000303_bb0055","unstructured":"National Cancer Institute. Common terminology criteria for adverse events and common toxicity criteria version 3.0. http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3."},{"key":"10.1136\/esmoopen-2017-000303_bb0060","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1158\/1078-0432.CCR-06-1542","article-title":"A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing","volume":"13","author":"Fracasso","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000303_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/esmoopen-2017-000303_bb0070","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1200\/JCO.2011.34.8888","article-title":"Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors","volume":"29","author":"Paz-Ares","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/esmoopen-2017-000303_bb0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/157488412799218806","article-title":"Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer","volume":"7","author":"Song","year":"2012","journal-title":"Curr Clin Pharmacol"},{"key":"10.1136\/esmoopen-2017-000303_bb0080","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1136\/esmoopen-2017-000303_bb0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000229752","article-title":"Risk of high-grade skin rash in cancer patients treated with cetuximab\u2013an antibody against epidermal growth factor receptor: systemic review and meta-analysis","volume":"77","author":"Su","year":"2009","journal-title":"Oncology"},{"key":"10.1136\/esmoopen-2017-000303_bb0090","first-page":"152","article-title":"Cetuximab-induced hypomagnesemia in patients with colorectal cancer","volume":"6","author":"Fakih","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1136\/esmoopen-2017-000303_bb0095","doi-asserted-by":"crossref","first-page":"6517","DOI":"10.1158\/1078-0432.CCR-06-0705","article-title":"Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors","volume":"12","author":"Tan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1136\/esmoopen-2017-000303_bb0100","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3892\/or.2014.3077","article-title":"Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS\/BRAF mutational status in colorectal cancer","volume":"31","author":"Seo","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1136\/esmoopen-2017-000303_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1517\/13543784.2015.971154","article-title":"Discontinued in 2013: oncology drugs","volume":"24","author":"Williams","year":"2015","journal-title":"Expert Opin Investig Drugs"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920323413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920323413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/esmoopen-2017-000303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:20:48Z","timestamp":1761855648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920323413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"alternative-id":["S2059702920323413"],"URL":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000303","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2018]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/esmoopen-2017-000303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 THE AUTHORS. Published by Elsevier Limited on behalf of European Society for Medical Oncology; Originally published by BMJ.","name":"copyright","label":"Copyright"}],"article-number":"e000303"}}